a

Clinical Studies

Magmaris® RMS’ clinical body of evidence keeps growing with new data from BIOSOLVE-IV of the full cohort with 2,066 patients at 24-month follow-up.

VIEW CLINICAL STUDIES

BIOSOLVE-IV Full cohort

24-month follow-up with 2,066 patients1

BIOSOLVE-IV registry – Results of the first cohort

Prof. Johan Bennett, UZ Leuven, Leuven, Belgium

View Study
TLF and ST
BIOSOLVE-IV registry – Results of the first cohort

Prof. Johan Bennett, UZ Leuven, Leuven, Belgium

View Study

1. Bennett J. Safety and Efficacy of the Resorbable Magnesium Scaffold, Magmaris in a Real-World Setting – 24-month Follow-up of the Full Cohort (2066 subjects) of the BIOSOLVE-IV Registry. Presented at: TCT, September 2022, Boston, USA. ClinicalTrials.gov: NCT02817802.

Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Magmaris is currently not available in the US.

© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.